Applications

1525.1 – Low dose rate brachytherapy for intermediate and high-risk prostate cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

Amendment to MBS item(s)

Service or technology in this application

LDR Brachytherapy is the insertion of tiny radioactive capsules or ‘seeds’ into the prostate gland. Generally, 80-120 seeds will be implanted. The radiation from the seeds targets the tumour and destroys the cancerous cells. The seeds are inserted via a hollow needle through the perineum. The procedure is guided by transrectal ultrasound.

Type: Therapeutic

Medical condition this application addresses

Cancer of the prostate gland that is classified as intermediate or high-risk. Intermediate risk prostate cancer is defined as having a Prostate Specific Antigen (PSA) measurement of 10-20 nanograms per millilitre of blood (ng/ml) and/or a Gleason score of 7 and/or a tumour classified as T2b-c. High-risk prostate cancer is classified as having a PSA of greater than 20 and/or a Gleason score of 8-10 and/or a tumour classified as T3 OR 2 or more intermediate risk features.

Previous applications

1525 – Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer

Consultation survey and deadlines

  • MSAC consultation: Closed Friday, 10 February 2023

Meetings to consider this application

  • PASC meeting: Bypassing PASC
  • ESC meeting: 9 to 10 February 2023
  • MSAC meeting: 30 to 31 March 2023